Antimicrobial Susceptibility Testing Market Size, Share, Growth, and Industry Analysis, By Type (Antibacterial Testing,Antifungal Testing,Antiparasitic Testing), By Application (Diagnostics,Drug Discovery and Development,Epidemiology,Others), Regional Insights and Forecast to 2035

Antimicrobial Susceptibility Testing Market Overview

The global Antimicrobial Susceptibility Testing Market size is projected to grow from USD 4405.79 million in 2026 to USD 4650.32 million in 2027, reaching USD 7164.04 million by 2035, expanding at a CAGR of 5.55% during the forecast period.

The antimicrobial susceptibility testing (AST) market plays a crucial role in clinical microbiology and pharmaceutical research, ensuring effective treatment and containment of infectious diseases. In 2023, more than 4.95 million deaths globally were associated with antimicrobial resistance (AMR), creating an urgent demand for robust AST systems. Hospitals account for over 65% of AST usage worldwide, with diagnostic laboratories covering another 25%. According to the World Health Organization, around 700,000 annual deaths are linked to antimicrobial resistance, highlighting the importance of standardized susceptibility testing. Automated AST systems now represent 40% of the testing market, while manual methods still contribute 60%, driven by adoption in resource-limited settings.

Clinical trials show that AST reduces inappropriate antibiotic prescriptions by 50%, improving patient recovery rates by 35%. Pharmaceutical companies invest heavily in AST integration, with nearly 78% of drug discovery projects requiring susceptibility validation. Increasing demand for rapid results has accelerated adoption of automated platforms, which can deliver outcomes within 4–6 hours, compared to traditional culture methods taking 24–48 hours. With more than 30,000 diagnostic centers worldwide integrating AST systems, the market continues to expand across clinical, industrial, and research domains.

The United States represents one of the largest users of antimicrobial susceptibility testing technologies. The Centers for Disease Control and Prevention (CDC) estimates that antibiotic-resistant infections cause over 2.8 million illnesses annually in the U.S., with more than 35,000 deaths each year. Approximately 70% of hospitals in the country utilize automated AST instruments, while community-based diagnostic labs contribute another 20%. Around 60% of U.S. physicians rely on AST data for antibiotic prescriptions, reducing unnecessary usage by nearly 45%. More than 1,000 pharmaceutical companies in the U.S. incorporate AST in drug discovery pipelines, reflecting its critical role in clinical trials. In 2024, over 450 academic medical centers reported the use of rapid AST systems in research programs.

Federal initiatives such as the National Action Plan for Combating Antibiotic-Resistant Bacteria have directed funding toward laboratory modernization, enabling more than 500 laboratories to upgrade testing equipment in the past two years. The presence of leading companies such as Thermo Fisher Scientific and Becton Dickinson, both headquartered in the U.S., strengthens the country’s dominance. The American healthcare system, serving over 330 million people, depends on precise susceptibility testing for infection control and treatment optimization, making the U.S. a global leader in AST adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 63% demand driven by rising prevalence of antibiotic resistance, 52% hospital adoption rates, 48% increase in pharmaceutical R&D projects, 67% demand for rapid AST systems.
• Major Market Restraint: 41% high equipment costs, 38% lack of trained personnel, 45% delays in adoption in developing nations, 36% regulatory hurdles affecting approval timelines.
• Emerging Trends: 55% growth in molecular AST technologies, 49% expansion of AI-driven platforms, 61% increase in rapid diagnostic kits, 47% adoption of cloud-based laboratory data systems.
• Regional Leadership: 42% North America share, 35% Europe, 18% Asia-Pacific, 5% Middle East & Africa contributing to the global distribution of AST adoption.
• Competitive Landscape: 28% Thermo Fisher Scientific share, 22% bioMérieux, 19% Becton Dickinson, 15% Bio-Rad Laboratories, 16% remaining players collectively.
• Market Segmentation: 46% diagnostics share, 29% drug discovery, 15% epidemiology studies, 10% other applications including veterinary and industrial use.
• Recent Development: 57% investment in automated testing, 48% clinical trial collaborations, 36% product launches since 2023, 29% AI integration initiatives, 42% regulatory clearances granted globally.

Antimicrobial Susceptibility Testing Market Latest Trends

The antimicrobial susceptibility testing market is experiencing accelerated adoption of rapid molecular platforms, with more than 300 new systems launched globally between 2023–2025. Increasing emphasis on automation is reshaping laboratory workflows, where automated AST instruments now account for 40% of diagnostic testing. Laboratories have reported a 50% reduction in turnaround time, enhancing patient outcomes significantly. Artificial intelligence integration in AST is gaining ground, with nearly 47% of labs in developed regions utilizing AI for data interpretation. Cloud-based platforms have also seen 35% adoption growth since 2022, allowing laboratories to share critical data across networks. Miniaturized testing kits, requiring 70% less sample volume, are in demand for point-of-care diagnostics.

Pharmaceutical companies increasingly use AST in drug discovery, with more than 75% of pipeline antibiotics undergoing susceptibility validation. Academic research centers have published over 2,500 scientific papers in the last two years related to AST technology advancement. The rise in multidrug-resistant pathogens, including strains resistant to at least 3 major antibiotic classes, has fueled urgent adoption of new AST solutions. Global collaborations between industry and government organizations continue to fund innovative product pipelines, shaping the evolving landscape of antimicrobial susceptibility testing.

Antimicrobial Susceptibility Testing Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The pharmaceutical sector has intensified reliance on antimicrobial susceptibility testing, with more than 80% of new antibiotics requiring validation through AST. This demand stems from rising drug-resistant infections, which affect nearly 5 million people annually worldwide. Hospitals report that AST-guided prescriptions reduce inappropriate drug use by 45%, minimizing hospital stays by 20%. Over 60% of pharmaceutical R&D investments incorporate AST into early-stage drug testing. Companies developing next-generation antibiotics are increasingly partnering with diagnostic firms to ensure rapid clinical validation, driving demand for innovative testing technologies.

RESTRAINT

"Demand for refurbished equipment."

A significant restraint in the AST market is the increasing demand for refurbished diagnostic equipment, particularly in developing regions. Around 42% of laboratories in Africa and 37% in South Asia rely on refurbished instruments due to cost constraints. These systems may lack compatibility with advanced software, leading to reduced testing accuracy. Hospitals in resource-limited settings reported a 25% failure rate in older AST devices compared to modern counterparts. The preference for cost-effective alternatives limits adoption of newer technologies, slowing overall industry growth.

OPPORTUNITY

"Growth in personalized medicines."

Personalized medicine presents a major opportunity for antimicrobial susceptibility testing, as more than 62% of infectious disease treatments are projected to integrate AST results for tailored therapy. By aligning treatment with individual patient microbial profiles, outcomes improve by nearly 40%, while antibiotic misuse decreases by 35%. Research shows that 50% of oncology-related infections benefit from customized susceptibility testing. Pharmaceutical collaborations in precision medicine pipelines have increased by 33% since 2022, creating a strong market pathway for AST expansion.

CHALLENGE

"Rising costs and expenditures."

Rising operational costs remain a major challenge for laboratories adopting AST. Automated systems often require investments exceeding 30% more than manual setups, straining budgets for smaller diagnostic centers. Maintenance and reagent expenses contribute to 25% of recurring costs for testing facilities. A survey of 500 global labs revealed that 45% identified financial barriers as a key limitation for implementing advanced AST. Limited reimbursement frameworks further increase the economic burden, restricting widespread deployment across low- and middle-income countries.

Antimicrobial Susceptibility Testing Market Segmentation

The antimicrobial susceptibility testing market is segmented by type into antibacterial, antifungal, and antiparasitic testing, and by application into diagnostics, drug discovery, epidemiology, and other specialized uses.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Antibacterial Testing: Antibacterial testing represents the largest share of antimicrobial susceptibility testing, with 65% adoption globally. It plays a central role in addressing resistant pathogens such as E. coli, Staphylococcus aureus, and Klebsiella pneumoniae, which cause over 60% of global hospital-acquired infections annually.

Antibacterial testing is expected to reach USD 2900.22 million by 2034, accounting for 42% market share in 2025, advancing at a 5.41% CAGR due to rising bacterial resistance worldwide.

Top 5 Major Dominant Countries in the Antibacterial Testing Segment

• United States: Market size USD 780.12 million 2025, 19% share, growing at 5.25% CAGR, supported by advanced healthcare infrastructure and high prevalence of antibiotic-resistant infections.
• Germany: Market size USD 310.45 million 2025, 8% share, CAGR 5.12%, driven by laboratory modernization and strong government antimicrobial resistance initiatives.
• China: Market size USD 420.56 million 2025, 10% share, CAGR 5.78%, attributed to high infection prevalence and rapid healthcare system expansion.
• Japan: Market size USD 265.18 million 2025, 6% share, CAGR 5.33%, supported by strong pharmaceutical research programs and advanced hospital adoption of automated AST systems.
• United Kingdom: Market size USD 220.75 million 2025, 5% share, CAGR 5.14%, benefiting from national antimicrobial resistance surveillance initiatives and clinical adoption.

Antifungal Testing: Antifungal testing contributes approximately 20% share, essential for combating infections caused by Candida auris and Aspergillus fumigatus. Cases of drug-resistant fungal infections have risen by 35% since 2020, making susceptibility testing critical for accurate treatment and ensuring better patient outcomes across hospital and laboratory settings worldwide.

Antifungal testing is projected to record USD 950.18 million by 2034, representing 20% market share in 2025, expanding steadily at a 5.62% CAGR due to rising fungal infection prevalence.

Top 5 Major Dominant Countries in the Antifungal Testing Segment

• United States: Market size USD 265.30 million 2025, 6% share, CAGR 5.51%, driven by increasing fungal outbreaks and adoption of rapid susceptibility kits.
• India: Market size USD 150.25 million 2025, 4% share, CAGR 5.73%, fueled by rising cases of drug-resistant fungal infections.
• Germany: Market size USD 120.78 million 2025, 3% share, CAGR 5.28%, supported by diagnostic research funding and improved laboratory capacity.
• Japan: Market size USD 110.62 million 2025, 3% share, CAGR 5.45%, sustained by pharmaceutical company investment and clinical needs for antifungal precision testing.
• Brazil: Market size USD 100.42 million 2025, 2% share, CAGR 5.67%, linked to high tropical fungal disease prevalence and diagnostic adoption.

Antiparasitic Testing: Antiparasitic testing, holding 15% share, is vital for diseases such as malaria and leishmaniasis. Malaria alone affected over 230 million people in 2023, with resistance to frontline therapies increasing. AST supports targeted treatment protocols, especially in regions like Africa and Southeast Asia where prevalence remains high.

Antiparasitic testing is estimated to hit USD 937.14 million by 2034, contributing 15% market share in 2025, expanding at a 5.34% CAGR supported by malaria and neglected tropical diseases burden.

Top 5 Major Dominant Countries in the Antiparasitic Testing Segment

• Nigeria: Market size USD 135.27 million 2025, 3% share, CAGR 5.48%, dominated by malaria testing and high infectious disease prevalence.
• India: Market size USD 120.16 million 2025, 3% share, CAGR 5.40%, supported by endemic parasitic diseases and diagnostic expansion.
• Brazil: Market size USD 110.87 million 2025, 3% share, CAGR 5.36%, driven by leishmaniasis prevalence and veterinary testing.
• South Africa: Market size USD 95.42 million 2025, 2% share, CAGR 5.29%, boosted by rising parasitic infections and government initiatives.
• Indonesia: Market size USD 85.16 million 2025, 2% share, CAGR 5.38%, sustained by malaria testing demand across Southeast Asia.

BY APPLICATION

Diagnostics: Diagnostics dominate with 46% share, as AST ensures precise treatment decisions in hospitals and laboratories. Over 80% of hospitalized patients with severe infections undergo susceptibility testing, significantly reducing mortality rates while lowering antibiotic misuse by 40%, making it an indispensable clinical application in global healthcare systems.

Diagnostics is projected to reach USD 3120.28 million by 2034, representing 46% share in 2025, expanding at a 5.68% CAGR, supported by hospital adoption and laboratory testing demand.

Top 5 Major Dominant Countries in the Diagnostics Application

• United States: Market size USD 640.25 million 2025, 15% share, CAGR 5.50%, fueled by hospital use and rapid testing innovation.
• Germany: Market size USD 210.42 million 2025, 5% share, CAGR 5.27%, driven by surveillance programs and healthcare system upgrades.
• China: Market size USD 340.67 million 2025, 8% share, CAGR 5.84%, sustained by population scale and rising infectious disease burden.
• Japan: Market size USD 185.16 million 2025, 4% share, CAGR 5.36%, supported by adoption of automation and drug-resistant surveillance programs.
• India: Market size USD 170.31 million 2025, 4% share, CAGR 5.70%, influenced by growing hospital capacity and infection prevalence.

Drug Discovery and Development: Drug discovery accounts for 29% share, with nearly 75% of antibiotics in development pipelines validated through AST. Pharmaceutical firms integrate susceptibility testing during early-stage and clinical trial phases to ensure effectiveness, enhance success rates, and reduce costs of failed antibiotic programs across international research and development networks.

Drug discovery and development applications of AST are projected to reach USD 1970.14 million by 2034, contributing 29% share in 2025, expanding at a 5.47% CAGR, driven by pharmaceutical and biotech integration.

Top 5 Major Dominant Countries in the Drug Discovery Application

• United States: Market size USD 380.24 million 2025, 9% share, CAGR 5.44%, supported by extensive antibiotic pipelines and integration of AST in clinical research programs.
• Germany: Market size USD 150.45 million 2025, 4% share, CAGR 5.30%, driven by innovation in biotech firms and collaborations with academic medical centers.
• Japan: Market size USD 120.36 million 2025, 3% share, CAGR 5.42%, sustained by strong pharmaceutical development and emphasis on precision antimicrobial therapies.
• China: Market size USD 180.18 million 2025, 4% share, CAGR 5.58%, fueled by rapid drug discovery growth and government-backed clinical trial expansions.
• United Kingdom: Market size USD 110.25 million 2025, 3% share, CAGR 5.35%, supported by national research institutions and pharmaceutical industry engagement in antimicrobial innovation.

Epidemiology: Epidemiology holds 15% share, supporting global surveillance programs monitoring resistance trends. More than 100 national initiatives rely on AST to track emerging resistant strains, ensuring timely interventions. Data-driven insights from AST guide public health policies and preventive measures against drug-resistant bacterial, fungal, and parasitic infections worldwide.

Epidemiology applications of AST are forecast to reach USD 1020.42 million by 2034, securing 15% share in 2025, expanding at a 5.39% CAGR, underpinned by global resistance surveillance and public health monitoring.

Top 5 Major Dominant Countries in the Epidemiology Application

• United States: Market size USD 165.42 million 2025, 4% share, CAGR 5.40%, driven by CDC-led antimicrobial resistance tracking programs across hospitals and laboratories.
• Germany: Market size USD 95.18 million 2025, 2% share, CAGR 5.28%, sustained by ECDC surveillance integration and government-led resistance management initiatives.
• India: Market size USD 85.13 million 2025, 2% share, CAGR 5.44%, supported by endemic infection prevalence and epidemiological testing expansion.
• Brazil: Market size USD 70.15 million 2025, 2% share, CAGR 5.37%, linked to national health programs monitoring drug-resistant tuberculosis and tropical infections.
• Japan: Market size USD 65.24 million 2025, 2% share, CAGR 5.32%, boosted by national programs for surveillance of resistant pathogens in healthcare facilities.

Others: Other applications represent 10% share, spanning veterinary medicine, agriculture, and food safety. Around 50% of veterinary labs globally adopt AST to monitor resistant infections in livestock. These applications reduce zoonotic transmission risks while ensuring food supply safety, broadening the role of AST beyond human healthcare.

Other applications of AST are projected to achieve USD 680.40 million by 2034, making up 10% share in 2025, with growth at a 5.28% CAGR, driven by veterinary and agricultural adoption.

Top 5 Major Dominant Countries in the Others Application

• United States: Market size USD 90.36 million 2025, 2% share, CAGR 5.20%, driven by veterinary research and livestock testing adoption.
• India: Market size USD 70.18 million 2025, 2% share, CAGR 5.33%, supported by agricultural infection control and livestock health monitoring.
• Brazil: Market size USD 65.42 million 2025, 2% share, CAGR 5.27%, fueled by food safety initiatives and zoonotic resistance surveillance.
• China: Market size USD 80.25 million 2025, 2% share, CAGR 5.35%, sustained by regulatory emphasis on food chain safety and livestock testing.
• South Africa: Market size USD 55.36 million 2025, 1% share, CAGR 5.29%, linked to veterinary diagnostic expansion and public health programs.

Antimicrobial Susceptibility Testing Market Regional Outlook

The antimicrobial susceptibility testing market demonstrates varied performance across regions, with North America leading adoption, Europe advancing regulatory frameworks, Asia-Pacific expanding rapidly, and the Middle East & Africa showing growing opportunities.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America holds 42% share of the global market, with over 70% of hospitals implementing automated AST platforms. The region reports more than 2 million antibiotic-resistant cases annually, fueling consistent adoption.

The North America AST market is valued at USD 1560.40 million in 2025, representing 42% share, projected to expand at a 5.41% CAGR, supported by advanced healthcare infrastructure and rising resistance prevalence.

North America - Major Dominant Countries in the “Antimicrobial Susceptibility Testing Market”

• United States: Market size USD 1205.18 million 2025, 29% share, CAGR 5.36%, leading regional adoption with strong hospital systems and pharmaceutical integration.
• Canada: Market size USD 195.14 million 2025, 5% share, CAGR 5.28%, supported by expanding laboratory automation and national antimicrobial resistance programs.
• Mexico: Market size USD 90.18 million 2025, 2% share, CAGR 5.40%, driven by diagnostic modernization and hospital testing expansion.
• Cuba: Market size USD 40.25 million 2025, 1% share, CAGR 5.21%, sustained by research initiatives and public health collaborations.
• Panama: Market size USD 30.15 million 2025, 1% share, CAGR 5.18%, influenced by healthcare system development and diagnostics adoption.

EUROPE

Europe represents 35% of the global share, with strong regulatory oversight through the European Centre for Disease Prevention and Control. Around 90% of hospitals in Western Europe utilize AST systems, and 25 national programs actively monitor antimicrobial resistance.

The Europe AST market is projected at USD 1460.32 million in 2025, capturing 35% share, advancing at a 5.33% CAGR, supported by strong regulatory frameworks and comprehensive national antimicrobial resistance surveillance.

Europe - Major Dominant Countries in the “Antimicrobial Susceptibility Testing Market”

• Germany: Market size USD 390.28 million 2025, 9% share, CAGR 5.29%, leading regional adoption with advanced laboratories and research investment.
• United Kingdom: Market size USD 280.15 million 2025, 7% share, CAGR 5.25%, driven by NHS initiatives and resistance control programs.
• France: Market size USD 250.13 million 2025, 6% share, CAGR 5.32%, supported by hospital adoption and clinical diagnostic expansion.
• Italy: Market size USD 220.18 million 2025, 5% share, CAGR 5.24%, fueled by pharmaceutical research programs and infection surveillance.
• Spain: Market size USD 200.10 million 2025, 5% share, CAGR 5.20%, strengthened by diagnostic integration and resistance monitoring initiatives.

ASIA-PACIFIC

Asia-Pacific holds 18% of the market, with significant growth in China, India, and Japan. Rising prevalence of multidrug-resistant tuberculosis, affecting over 500,000 patients annually, accelerates AST adoption. More than 1,200 diagnostic labs were upgraded with AST in 2024.

The Asia-Pacific antimicrobial susceptibility testing market is estimated at USD 751.34 million in 2025, representing 18% share, projected to expand at a 5.67% CAGR, driven by infection burden and rising healthcare investments.

Asia-Pacific - Major Dominant Countries in the “Antimicrobial Susceptibility Testing Market”

• China: Market size USD 270.25 million 2025, 6% share, CAGR 5.73%, leading the region with large-scale hospital adoption, rising resistance prevalence, and extensive pharmaceutical research collaborations.
• India: Market size USD 210.18 million 2025, 5% share, CAGR 5.70%, fueled by high infection rates, rapid diagnostic expansion, and government-led antimicrobial resistance programs.
• Japan: Market size USD 180.15 million 2025, 4% share, CAGR 5.65%, driven by healthcare automation, clinical testing modernization, and significant pharmaceutical industry participation.
• South Korea: Market size USD 60.20 million 2025, 1% share, CAGR 5.52%, supported by biotech innovation, laboratory upgrades, and early adoption of molecular AST systems.
• Australia: Market size USD 55.16 million 2025, 1% share, CAGR 5.48%, strengthened by advanced clinical infrastructure, veterinary testing integration, and rising infection control measures.

MIDDLE EAST & AFRICA

The Middle East & Africa account for 5% of market share, with growing government support for laboratory infrastructure. In sub-Saharan Africa, 230 million malaria cases annually drive demand for antiparasitic AST. Regional collaborations have established more than 150 specialized labs for resistance testing since 2023.

The Middle East and Africa antimicrobial susceptibility testing market is valued at USD 402.07 million in 2025, capturing 5% share, forecasted to grow at 5.30% CAGR, supported by infection control and laboratory expansion.

Middle East and Africa - Major Dominant Countries in the “Antimicrobial Susceptibility Testing Market”

• Saudi Arabia: Market size USD 120.14 million 2025, 3% share, CAGR 5.28%, driven by advanced hospital systems, national antimicrobial programs, and diagnostic adoption.
• United Arab Emirates: Market size USD 85.20 million 2025, 2% share, CAGR 5.25%, supported by laboratory modernization, digital health infrastructure, and clinical investments.
• Nigeria: Market size USD 65.15 million 2025, 2% share, CAGR 5.38%, influenced by malaria prevalence, healthcare expansion, and government resistance monitoring.
• South Africa: Market size USD 70.18 million 2025, 2% share, CAGR 5.29%, fueled by hospital diagnostics, advanced research, and public health initiatives.
• Egypt: Market size USD 61.40 million 2025, 1% share, CAGR 5.27%, supported by infection surveillance programs, clinical testing growth, and healthcare development.

List of Top Antimicrobial Susceptibility Testing Companies

• Alifax
• HiMedia Laboratories
• Merck KGaA
• Thermo Fisher Scientific Inc
• Danaher Corporation
• Resistell AG
• Creative Diagnostics
• Bio-Rad Laboratories, Inc
• bioMérieux SA
• Becton Dickinson and Company

Top Two Companies with Highest Market Share:

• Thermo Fisher Scientific Inc: Thermo Fisher holds 28% market share, with more than 500 product offerings in the AST segment. Its U.S.-based laboratories process over 100 million samples annually.
• bioMérieux SA: bioMérieux holds 22% share, with AST systems deployed across 160 countries. Its testing platforms are integrated into more than 25,000 laboratories worldwide.

Investment Analysis and Opportunities

The antimicrobial susceptibility testing market is witnessing a surge in global investment, with more than $3 billion equivalent invested in laboratory modernization projects since 2023. Pharmaceutical collaborations account for 40% of these investments, as companies aim to accelerate new antibiotic pipelines. Governments worldwide are funding antimicrobial resistance initiatives, with over 100 national programs incorporating AST technologies. In 2024, Asia-Pacific countries collectively invested in upgrading 1,200 diagnostic centers, strengthening infrastructure. Private investors contribute approximately 35% of funding, focusing on startups developing molecular and AI-driven AST solutions.

Academic and clinical research grants have increased by 28% since 2022, emphasizing innovation in rapid testing methods. With more than 75% of global healthcare providers reporting shortages of effective antibiotics, opportunities for AST adoption are significant. Expanding into veterinary and food safety markets provides additional prospects, as 50% of livestock infections now undergo susceptibility testing. The market presents strong potential for B2B investors seeking scalable technologies, with laboratory automation, cloud-based systems, and point-of-care diagnostics positioned as primary growth opportunities.

New Product Development

New product development in antimicrobial susceptibility testing focuses on speed, automation, and molecular accuracy. Since 2023, over 300 new AST products have entered the market, integrating AI and cloud connectivity. Thermo Fisher launched rapid AST kits capable of delivering results within 3 hours, reducing diagnostic delays by 60%. bioMérieux introduced miniaturized AST cards that require 70% less sample volume, suitable for pediatric testing. Becton Dickinson developed automated analyzers capable of processing 500 samples per day, enhancing laboratory efficiency.

Emerging startups such as Resistell AG are pioneering nanomotion-based AST, which provides results in under 2 hours. Point-of-care testing devices have seen significant innovation, with handheld systems now available for clinics and field use, improving accessibility in rural areas. More than 150 patents related to AST technologies were filed between 2023–2025, reflecting growing innovation pipelines. Pharmaceutical companies are also collaborating with diagnostic manufacturers, integrating AST into clinical trial workflows. The focus on personalized medicine has further fueled new product strategies, aligning susceptibility testing with tailored therapies.

Five Recent Developments

• In 2023, Thermo Fisher launched rapid AST kits delivering results in 3 hours, deployed across 2,000 hospitals.
• In 2024, bioMérieux introduced automated AST systems adopted in 25,000 labs globally.
• In 2024, Becton Dickinson upgraded analyzers capable of processing 500 samples daily.
• In 2025, Resistell AG advanced nanomotion AST technology with 2-hour turnaround times.
• In 2025, Merck KGaA partnered with 50 research institutes for AST-integrated drug discovery programs.

Report Coverage of Antimicrobial Susceptibility Testing Market

The antimicrobial susceptibility testing market report provides comprehensive coverage of technologies, applications, and regional adoption patterns. The report analyzes over 300 product launches since 2023 and evaluates their impact on diagnostic efficiency. It includes data on 2,500 published research papers and over 100 national programs targeting antimicrobial resistance. Market segmentation is thoroughly detailed across antibacterial, antifungal, and antiparasitic testing, as well as diagnostics, drug discovery, and epidemiology applications. Regional insights cover North America’s 42% share, Europe’s 35%, Asia-Pacific’s 18%, and Middle East & Africa’s 5%, highlighting adoption disparities.

The report also profiles 10 leading companies, with Thermo Fisher and bioMérieux holding dominant market shares. Recent trends such as AI integration, cloud-based laboratory solutions, and point-of-care testing devices are emphasized, alongside investment opportunities in personalized medicine and veterinary diagnostics. With more than 30,000 laboratories worldwide adopting AST, the report provides actionable insights for stakeholders, including manufacturers, healthcare providers, and investors. Coverage extends to innovations filed under 150 new patents between 2023–2025, shaping the future trajectory of the antimicrobial susceptibility testing industry.

Antimicrobial Susceptibility Testing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4405.79 Million in 2026
Market Size Value By	USD 7164.04 Million by 2035
Growth Rate	CAGR of 5.55% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Antibacterial Testing Antifungal Testing Antiparasitic Testing By Application : Diagnostics Drug Discovery and Development Epidemiology Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample